ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Craig H. Selzman
Robert C. McIntyre, Jr
Alden H. Harken
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selzman, C. H.
Right arrow Articles by Harken, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selzman, C. H.
Right arrow Articles by Harken, A. H.

Ann Thorac Surg 1999;67:1227-1231
© 1999 The Society of Thoracic Surgeons

Original Articles

The NF{kappa}B inhibitory peptide, I{kappa}B{alpha}, prevents human vascular smooth muscle proliferation

Craig H. Selzman, MDa, Brian D. Shames, MDa, Robert C. McIntyre, Jr, MDa, Anirban Banerjee, PhDa, Alden H. Harken, MDa

a Department of Surgery, University of Colorado Health Sciences Center, Denver, Colorado, USA

Address reprint requests to Dr Selzman, Dept of Surgery, University of Colorado Health Sciences Center, Campus Box C-320, 4200 East Ninth Ave, Denver, CO 80262
e-mail: craig.selzman{at}UCHSC.edu

Presented at the Thirty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, January 25–27, 1999.

Background. Vessel injury results in an inflammatory response characterized by the elaboration of cytokines and growth factors, which ultimately influence vascular smooth muscle cell (VSMC) growth and contribute to atherogenesis. Nuclear factor-kappa B (NF{kappa}B) is a central transcription factor important in mediating stress and inflammatory-induced signals. We hypothesized that strategies aimed at inhibiting NF{kappa}B would abrogate mitogen-induced human VSMC proliferation.

Methods. Human aortic VSMC were stimulated with basic fibroblast growth factor (FGF) and tumor necrosis factor-{alpha} (TNF), and proliferation was quantified by a colormetric assay. The influence of NF{kappa}B on VSMC proliferation was examined by both nonspecific NF{kappa}B blockade with calpain inhibitor-1 (CI-1) and dexamethasone (Dex) and specific NF{kappa}B blockade with liposomal delivery of the NF{kappa}B inhibitory peptide, I{kappa}B{alpha}.

Results. FGF and TNF induced concentration-dependent VSMC proliferation (p < 0.002). Neither CI-1, Dex, nor liposomal I{kappa}B{alpha} influenced proliferation of unstimulated VSMC. However, both FGF- and TNF-stimulated VSMC proliferation was inhibited to the level of control with CI-1, Dex, and liposomal I{kappa}B{alpha} (p < 0.001).

Conclusion. The mitogenic effect of FGF and TNF on human arterial VSMC may be prevented by inhibiting NF{kappa}B. Furthermore, liposomal delivery of endogenous inhibitory proteins such as I{kappa}B{alpha} may represent a novel, therapeutically accessible method for selective transcriptional suppression in the response to vascular injury.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. H. Harken
The world of inhibitory {kappa}B
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2624 - H2625.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. Raj, P. Kanellakis, G. Pomilio, G. Jennings, A. Bobik, and A. Agrotis
Inhibition of Fibroblast Growth Factor Receptor Signaling Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1845 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. P.J. de Winther, E. Kanters, G. Kraal, and M. H. Hofker
Nuclear Factor {kappa}B Signaling in Atherogenesis
Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 904 - 914.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Wang, P. J. Rao, M. R. Castresana, and W. H. Newman
TNF-{alpha} induces proliferation or apoptosis in human saphenous vein smooth muscle cells depending on phenotype
Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H293 - H301.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
C. H. Selzman, M. G. Netea, M. A. Zimmerman, A. Weinberg, L. L. Reznikov, F. L. Grover, and C. A. Dinarello
Atherogenic effects of Chlamydia pneumoniae: refuting the innocent bystander hypothesis
J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 688 - 693.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
R. C. Brown, K. S. Mark, R. D. Egleton, J. D. Huber, A. R. Burroughs, and T. P. Davis
Protection against hypoxia-induced increase in blood-brain barrier permeability: role of tight junction proteins and NF{kappa}B
J. Cell Sci., February 15, 2003; 116(4): 693 - 700.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. H. Selzman, S. A. Miller, M. A. Zimmerman, F. Gamboni-Robertson, A. H. Harken, and A. Banerjee
Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation
Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1455 - H1461.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. H. Selzman, S. A. Miller, and A. H. Harken
Therapeutic implications of inflammation in atherosclerotic cardiovascular disease
Ann. Thorac. Surg., June 1, 2001; 71(6): 2066 - 2074.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 by The Society of Thoracic Surgeons.